Connect Biopharma drops after Phase 2 rademikibart endpoint miss
Connect Biopharma plunged after Phase 2 Seabreeze missed the primary endpoint for rademikibart in asthma, despite halving ED/unscheduled visits and improving lung function as a secondary endpoint.
Connect Biopharma Holdings Ltd. (NASDAQ:CNTB) fell after Phase 2 Seabreeze missed its primary endpoint for rademikibart in asthma. The company said the drug halved ED/unscheduled visits, improved lung function as a secondary endpoint and showed placebo-like safety. Canaccord cut its $7 price target.